Intensity Modulated Total Marrow Irradiation

A Phase I Study of Intensity Modulated Total Marrow Irradiation (IMTMI) in Addition to Fludarabine/Melphalan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
30 patients (estimated)
Sponsors
University of Chicago
Collaborators
National Cancer Institute (NCI)
Tags
Allogeneic Stem Cell Transplant, Chemotherapy, Radiation Therapy
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1597
NCT Identifier
NCT02333162

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.